Prognostic significance of WT1 expression in soft tissue sarcoma by 최경운
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Kim et al. World Journal of Surgical Oncology 2014, 12:214
http://www.wjso.com/content/12/1/214RESEARCH Open AccessPrognostic significance of WT1 expression in soft
tissue sarcoma
Ahrong Kim1, Eun Young Park2, Kyungbin Kim3, Jeong Hee Lee3, Dong Hoon Shin2,3, Jee Yeon Kim2,3,
Do Youn Park1,2, Chang Hun Lee1,2, Mee Young Sol2,3, Kyung Un Choi2,3*, Jeung Il Kim4 and In Sook Lee5Abstract
Background: Soft tissue sarcomas (STS) are rare. We evaluated the WT1 protein expression level in various types of
STS and elucidated the value of WT1 as a prognostic factor and a possible therapeutic target.
Methods: Immunohistochemical staining for WT1 was performed in 87 cases of STS using formalin-fixed,
paraffin-embedded blocks. The correlation between WT1 expression and clinicopathological factors was analyzed.
Survival analysis was conducted in 67 patients. We assessed the validity of WT1 immunohistochemistry as an index
of WT1 protein expression using Western blot analysis.
Results: WT1 expression was noted in 47 cases (54.0%). Most rhabdomyosarcomas and malignant peripheral nerve
sheath tumors showed WT1 expression (91.7% and 71.4%, respectively; P = 0.005). WT1 expression was related to
higher FNCLCC histologic grade and AJCC tumor stage. In the group with high grade STS, strong WT1 expression
was correlated with better survival (P = 0.025). The immunohistochemical results were correlated quantitatively with
the staining score and the concentration of the Western blot band.
Conclusions: This study demonstrates that various types of STS show positive immunostaining for WT1 and that
WT1 expression has a prognostic significance. So STS should be considered candidates for WT1 peptide–based
immunotherapy.Background
The Wilms’ tumor gene (WT1) located at chromosome
11p13 was originally identified as a tumor-suppressor
gene associated with Wilms’ tumor, a kidney neoplasm
of childhood. The WT1 is mutated in the germline of
children with a genetic predisposition to Wilms’ tumor
and is inactivated in a subset of sporadic Wilms’ tumors
[1-3]. The WT1 gene encodes a zinc-finger transcription
factor, which regulates target genes, some of which are
related to cell differentiation, proliferation, and apop-
tosis, and binds to specific sequences within the pro-
moter regions of the WT1 gene itself. It also binds to a
number of other genes, such as insulin like growth
factor-II, platelet-derived growth factor A chain, and
IGH-I receptor [4-8]. The WT1 gene also has a central* Correspondence: kuchoi@pusan.ac.kr
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unless otherwise stated.role in embryonic development [9] and is normally
expressed in a limited set of tissues, including gonad,
uterus, kidney, and mesothelium [10-12].
Recent studies have suggested that WT1 has an import-
ant role not only as a tumor suppressor, but also as a
tumor promoter in various kinds of neoplasm. Many stud-
ies have shown that the wild-type WT1 gene is expressed
in leukemia [13,14], breast cancer [15,16], lung cancer
[17], ovarian cancer [18], mesothelioma [19], renal cell
carcinoma [20], and bone and soft tissue sarcomas [21,22].
However, the molecular pathway underlying the activity
of WT1 is still unclear. It is also not known whether the
WT1 gene is a tumor suppressor gene or an oncogene,
or whether it has a biphasic function.
Many recent studies have highlighted the potential of
the WT1 protein as a tumor-associated antigen and a
candidate for targeted cancer immunotherapy. Clinical tri-
als have suggested the safety and clinical efficacy of WT1
immunotherapy in cancer [23-25]. In 2007, the National
Cancer Institute immunotherapy agent workshop [26]
was held to rank agents with high potential to serve as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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WT1 ranked the highest out of 75 cancer antigens priori-
tized. These results imply that a new era of WT1-targeted
therapy is imminent.
Soft tissue sarcomas (STS) are rare malignant tumors
accounting for about 1% of adult and 15% of pediatric
malignancies [27]. WT1 expression in STS, especially at
the protein level, is not well documented. Ueda et al.
[21] reported that various types of bone and soft tissue
sarcomas frequently overexpress the wild-type WT1 gene.
They also reported that the WT1 mRNA expression level
can serve as a potent prognostic indicator in STS [22].
Nakatsuka et al. [28] reported that 70% of various types of
STS expressed positive immunostaining for WT1.
In the current study, we evaluated the WT1 protein
expression level by immunohistochemistry in various
types of STS and assessed the validity of WT1 immuno-
histochemistry as an index of WT1 protein expression
by comparison with Western blot analysis. In addition,
we elucidated the value of WT1 as a prognostic factor
and the possibility of WT1 immunotherapy for STS.
Methods
Patients and tissue samples
STS samples were obtained from surgical operations car-
ried out at Pusan National University Hospital, Korea,
from 1998 to 2009. A total of 87 patients who underwent
surgical resection for primary STS were included. Various
clinicopathological data, including patient age, tumor size,
metastasis at diagnosis, and details on the tumor grade
and stage were obtained from the primary pathology re-
ports and patient chart review. The histological diagnosis
was determined by World Health Organization criteria,
and the histological grade was determined according to
the Federation Nationale des Centres de Lutte Contre
le Cancer (FNCLCC) scheme. Surgical staging was de-
termined based on the criteria recommended by the
American Joint Committee on Cancer (AJCC). The
aforementioned clinicopathological data were available
for all 87 patients.
Fresh tumor tissue samples were used. The biospeci-
mens for this study were provided by the Pusan National
University Hospital, a member of the National Biobank
of Korea, which is supported by the Ministry of Health,
Welfare, and Family Affairs. All samples derived from
the National Biobank of Korea were obtained with in-
formed consent under institutional review board-approved
protocols. The samples were snap-frozen in liquid nitrogen
shortly after biopsy or resection and stored at −80°C until
use. They included four cases of liposarcoma, one case of
fibrosarcoma, one case of leiomyosarcoma, one case of
malignant fibrous histiocytoma, and one case of synovial
sarcoma. The results of analyses of the samples’ immuno-
histochemical expression and the Western blot werecompared to validate the immunohistochemistry as an
index of WT1 protein expression.Immunohistochemistry
Immunohistochemistry was performed on serial 4-μm
thick paraffin sections. The paraffin sections were deparaf-
finized in xylene and rehydrated in a descending ethanol
series. Bond Epitope Retrieval Solution 1 [pH ~ 6] or Bond
Epitope Retrieval Solution 2 [pH ~ 9] (Leica Microsystems,
Wetzlar, Germany) were used for antigen retrieval. Mouse
monoclonal WT1 antibody (dilution 1:100, Clone 6 F-H2,
Dako) was applied on the slides. Immunohistochemical
staining was performed with a Leica Bond-MAX™ auto-
stainer (Leica Microsystems, Berlin, Germany) and the
peroxidase/DAB Bond™ Polymer Refine Detection System
(Leica Microsystems) was used for visualization.Assessment of immunohistochemical staining
Evaluation of immunohistochemical staining was per-
formed by two independent pathologists (Kim A and Choi
KU). The stainings were scored while the pathologists
were blinded to the clinicopathological data. WT1 was
considered positive when cytoplasm and/or nuclear stain-
ing were observed [28]. The extent of expression was eval-
uated semi-quantitatively based on a staining score system
after comparing the results of the immunostaining with
those of RT-PCR [29]. The intensity of the staining and
the proportion of the positive staining area were con-
sidered together. The intensity of the immunostaining
was graded as 0 (negative), 1 (weak), 2 (moderate), or 3
(strong), and then the percentage of positive tumor
cells was evaluated. The scoring system was based on
the multiplication of the percentage and the intensity
grade of positive cells, with the cells graded as negative
(0–20), weak (21–80), moderate (81–180), or strong
(181–300). Blood vessels, which open directly between
tumor cells in sarcomas, were used as a positive control.
Finally, to perform a statistical analysis, we grouped the
four staining groups into two categories: negative (negative
group) and positive expression (weak, moderate, and
strong group).Western blot analysis
Proteins from the fresh frozen sarcoma tissue were loaded
onto each well of the gel, separated by SDS-PAGE, and
then transferred onto a membrane (CP-BU new, Agfa).
After blocking nonspecific binding, the membrane was
immunoblotted with the anti-WT1 mouse monoclonal
antibody WLM 04 (Santa Cruz Biotechnology), followed
by incubation with the appropriate secondary antibody
conjugation with alkaline phosphatase.
Table 1 Clinicopathological features (n = 87)
Clinicopathologic data Cases
Age (median, mean) 50, 49
Age
Less than 50 yrs 40
More than 50 yrs 47
Sex
Male 49
Female 38
Histologic type
Liposarcoma 26
MFH 21
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All statistical analyses were performed using SPSS for
Windows software version 19.0 (SPSS Inc., Chicago, IL,
USA). Pearson’s χ2 test was used to study the associa-
tions between the clinicopathological factors and WT1
expression. Overall survival (OS) was defined as the time
being from the day of diagnosis until the death of the
patient by Kaplan-Meier survival curves. Disease-free
survival (DFS) was defined as the time from the day of
diagnosis until any event including death, distant metasta-
sis, or recurrence, by Kaplan-Meier survival curves. For all
tests, a P value of less than 0.05 was considered significant.
The survival analysis was performed between 1998 and
2007.Rhabdomyosarcoma 12
Leiomyosarcoma 6
MPNST 7
Synovial sarcoma 7
Fibrosarcoma 5
Others* 3
Site
Thigh 27
Upper arm 5
Retroperitoneum 8
Head and neck 11
Buttock 5
Forearm 5Results
Clinicopathological data
Patient age ranged from 1 to 82 years (median age
50 years) and there were 49 males and 38 females.
There were 26 cases of liposarcoma, 21 cases of malig-
nant fibrous histiocytoma, 12 cases of rhabdomyosar-
coma, 6 cases of leiomyosarcoma, 7 cases of malignant
peripheral nerve sheath tumor (MPNST) and synovial
sarcoma, 5 cases of fibrosarcoma, and 3 cases of other
sarcomas including epithelioid sarcoma and alveolar
soft part sarcoma. Three patients had metastatic sarcoma
upon initial diagnosis. Other detailed clinicopathological
data are shown in Table 1.Back 3
Lower leg 4
Others 19
Tumor size
<5 cm 13
>5 cm 74
FNCLCC grade
1 17
2 37
3 33
AJCC stage
1 17WT1 immunohistochemistry
A total of 87 STS samples were used for the determination
of WT1 expression. All of the samples showed positive
staining for feeding blood vessels, demonstrating that the
staining was reliable and appropriate (Figure 1). Specific
staining for WT1 was observed in the cytoplasm of tumor
cells, but in a few cases, both cytoplasmic and nuclear
staining was observed. There was negative staining in 40
specimens (negative, 46.0%). The staining for WT1
showed weak positivity in 6 (6.9%), moderate positivity in
15 (17.2%), and strong positivity in 26 (29.9%). Thus, WT1
expression was noted in 47 (54.0%) of the 87 cases by
immunohistochemistry.2 42
3 25
4 3
Total 87
*Others include 2 alveolar soft part sarcomas and 1 epithelioid sarcoma.
MFH, Malignant fibrous histiocytoma; MPNST, Malignant peripheral nerve
sheath tumor; FNCLCC, Federation Nationale des Centres de Lutte Contre le
Cancer; AJCC, American Joint Committee on Cancer.Correlation between WT1 expression level and
clinicopathological characteristics of STS
Table 2 summarizes the association of WT1 expression
in STS with the clinicopathological parameters. WT1 ex-
pression was associated with the histological diagnosis.
Rhabdomyosarcoma was strongly correlated with WT1
expression (91.7%, P = 0.005). WT1 expression was asso-
ciated with high FNCLCC grade and advanced tumor
stage (P = 0.000).
AB
C
D
Figure 1 Immunohistochemical staining of WT1 (×400). (A) Negative staining. Note that this section shows positive staining for blood vessels.
(B) Weak staining. (C) Moderate staining. (D) Strong staining.
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Clinical follow-up data were available for 63 patients.
The median follow-up was 29 months (1–187). Twenty-
seven patients developed local recurrence, and 17 patients
developed metastasis; 25 patients (39.6% of total patients)
died of the disease during the follow-up period.
In the group for which follow-up data were available
(n = 63), 15 (45.4%) of 33 patients with WT1 expression
died of the disease, compared to 10 (33.3%) of 30 patients
without WT1 expression; this difference was not statisti-
cally significant (P = 0.326). Twenty-three (69.6%) of 33
patients with WT1 expression had disease-related events,
including recurrence, distant metastasis, and death,
compared to 18 (60.0%) of 30 patients without WT1 ex-
pression; this difference was not statistically significant
(P = 0.420) (Table 3).
In the survival analysis of the group with high grade
STS (n = 50), WT1 expression was not correlated with
OS and DFS (P = 0.710, P = 0.728, respectively). How-
ever, 6 (35.2%) of 17 patients with strong WT1 expres-
sion and 15 (45.4%) of 33 patients in a remnant group
(including negative, weak, and moderate expression)
died of the disease. Strong WT1 expression was associ-
ated with a better outcome in the group with high grade
sarcoma (P = 0.025) (Figure 2).
Western blot analysis
To determine the accuracy of the immunohistochemical
staining as an index of protein expression, the results of
the Western blot analysis were compared with those of
the immunohistochemical staining. The Western blot
analysis revealed not only that immunohistochemical
staining is a reliable method for the evaluation of proteinexpression but also that the immunohistochemistry
correlates quantitatively with the staining score and the
concentration of the Western blot band (Table 4 and
Figure 3).
Discussion
In this study, we investigated WT-1 expression at the
protein level by immunohistochemistry in various kinds
of STS and examined the correlation between the WT1
expression level and clinicopathological factors.
The study of WT1 in STS is limited. To our knowledge,
this is the largest cohort study of WT1 expression in STS
to date. There also appears to have been no report about
the relationship between WT1 expression at the protein
level by immunohistochemistry and prognosis.
More than half (54.0%) of STS showed positive expres-
sion for WT1 immunostaining, demonstrating that more
than half of STS are candidates for WT1-targeted im-
munotherapy. Nakatsuka et al. [28] reported that 70% of
32 soft tissue sarcomas showed positivity for WT1 im-
munostaining and that 100% of rhabdomyosarcomas,
malignant fibrous histiocytomas, MPNSTs, and clear cell
sarcomas showed positive staining for WT1 when using
monoclonal (6 F-H2) antibody. The higher frequency of
WT1 positivity in their study was likely due to the fact
that they considered only the positivity of staining, while
we considered not only the positivity, but also the inten-
sity and the proportion of positivity. After multiplying
the percentage and the intensity grade of the positive
cells, a score between 0 and 20 was considered negative
in the present study. Our results revealed that rhabdo-
myosarcoma and MPNST showed frequent WT1 expres-
sion (91.7% and 71.4%, respectively). It seems reasonable
Table 2 Correlation between WT1 expression and clinicopathological factors
Clinicopathologic parameters WT-1 protein expression
Absent, n = 40 (46.0%) Present, n = 47 (54.0%) P value
Age
<50 19 (47.5) 21 (52.5) 0.793
>50 21 (44.7) 26 (55.3)
Histologic type
Liposarcoma 20 (76.9) 6 (23.1) 0.005
MFH 9 (42.9) 12 (57.1)
Leiomyosarcoma 2 (33.3) 4 (66.7)
Rhabdomyosarcoma 1 (8.3) 11 (91.7)
MPNST 2 (28.6) 5 (71.4)
Synovial sarcoma 3 (42.9) 4 (57.1)
Fibrosarcoma 1 (20.0) 4 (80.0)
Others 2 (40.0) 3 (60.0)
Size
<5 cm 3 (23.1) 10 (76.9) 0.072
>5 cm 37 (50.0) 37 (50.0)
Metastasis at Dx
Absent 38 (45.8) 45 (54.2) 0.869
Present 2 (50.0) 2 (50.0)
FNCLCC grade
1 16 (94.1) 1 (5.9) 0.000
2 14 (37.8) 23 (62.2)
3 10 (30.3) 23 (69.7)
Modified grade *
Low 16 (94.1) 1 (5.9) 0.000
High 24 (34.3) 46 (65.7)
AJCC stage
1 15 (83.3) 3 (16.7) 0.003
2 14 (34.1) 27 (65.9)
3 9 (36.0) 16 (64.0)
4 2 (66.7) 1 (33.3)
AJCC modified**
Localized 15 (83.3) 3 (16.7) 0.000
Advanced 25 (36.2) 44 (63.8)
*FNCLCC grade was divided into 2 groups, low grade including FNCLCC group 1 and high grade including FNCLCC grade 2 and 3.
**AJCC stage 1 was defined as localized disease and AJCC stage 2, 3, and 4 were defined as advanced disease.
MFH, Malignant fibrous histiocytoma; MPNST, Malignant peripheral nerve sheath tumor; FNCLCC, Federation Nationale des Centres de Lutte Contre le Cancer;
AJCC, American Joint Committee on Cancer.
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especially in rhabdomyosarcoma and MPNST.
Ueda et al. reported that the WT1 gene was frequently
overexpressed in various types of STS [21] and that
WT1 mRNA overexpression was significantly associated
with a poor prognosis. However, the current study did
not reveal any association between WT1 expression and
OS or DFS. The results for OS and DFS among highgrade STS were similar. It is interesting that strong
WT1 expression was correlated with better survival in
the group of high grade STS. Only 2 out of 10 cases of
high grade rhabdomyosarcoma with strong WT1 expres-
sion died as a result of the disease, while all two patients
of high grade rhabdomyosarcoma with weak WT1 ex-
pression died of disease. Although Ueda et al. deter-
mined that the WT1 mRNA level was correlated with
Table 3 Correlation between WT1 expression and survival
WT-1 protein expression
Absent, n = 30
(47.6%)
Present, n = 33
(52.4%)
P value
Survival*
Survival 20 (52.6) 18 (47.4) 0.326
Death 10 (40.0) 15 (60.0)
Any event*,**
Absent 12 (54.5) 10 (45.5) 0.420
Present 18 (43.9) 23 (56.1)
*Evaluation for survival and any event was performed among patients
between 1998 and 2007.
**Any events include local recurrence, distant metastasis, and death
during follow-up.
Table 4 WT1 expression by immunohistochemistry for
comparison with western blot
WT-1 protein expression
Intensity % of
positive cells
Score
Case 1 Liposarcoma 1 10 10 Negative
Case 2 Liposarcoma 1 20 20 Negative
Case 3 Synovical sarcoma 1 40 40 Positive
Case 4 Liposarcoma 2 20 40 Positive
Case 5 Malignant fibrous
histiocytoma
2 20 40 Positive
Case 6 Liposarcoma 1 45 45 Positive
Case 7 Fibrosarcoma 2 40 80 Positive
Case 8 Leiomyosarcoma 2 95 190 Positive
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munohistochemistry [21], this was the case in only 4 of
52 and 3 out of 36 samples, respectively. Therefore, the
correlation between the protein and mRNA level of the
WT1 gene has not been conclusively validated. Based on
the results of the comparison of the immunostaining
with those of the western blot analysis, the current study
demonstrates that WT1 immunohistochemical staining
is a reliable method for evaluating the WT1 protein ex-
pression level. As previously mentioned, it is not known
whether the WT1 gene is a tumor suppressor or an
oncogene, or whether it has a biphasic function. The
molecular pathway also remains to be further defined.
Therefore, further studies on the correlation between
the protein and mRNA of the WT1 gene in larger cohortFigure 2 Overall survival of high grade soft tissue sarcomas in
low WT1 expression level and high WT1 expression level
(P = 0.025).are required, together with survival analysis, to validate
of the WT1 expression level as a prognostic factor.
High expression of the WT1 gene in solid cancers and
leukemia suggested that the WT1 protein might be a
possible tumor-associated antigen. In a mouse model,
murine WT1 protein-derived, MHC class I-restricted
WT1 peptides were tested to induce WT1-specific cyto-
toxic T lymphocytes (CTLs). The WT1-specific CTLs in
mice lysed WT1-expressing tumor cells showed no
evidence of histopathological damage of organs that
physiologically expressed WT1 [23,30,31]. The mechan-
ism by which WT1-specific CTLs ignore WT1-expressing
normal cells is not clear, but there are four probable
mechanisms. First, it may be due to normal cells having
lower WT1 expression than tumor cells. However, this is
unlikely considering that the level of WT1 expression in
CD34+ normal hematopoietic progenitor cells is as high
as in leukemic cells. Second, the expression of MHC class
I molecules may be lower in physiologically WT1 express-
ing normal cells than in WT1 expressing tumor cells.
Third, the WT1 peptide presentation of WT1-expressingFigure 3 Western blot analysis revealed that
immunohistochemical expression of WT1 is a precise method
of evaluation for WT1 protein expression, compared with
counterpart immunohistochemical staining (see Table 3).
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mal cells do not express, or weakly express, cell surface
costimulatory molecules required for recognition and/or
killing by WT1-specific CTLs [24].
WT1 peptide immunotherapy has also been confirmed
to have the clinical effectiveness and safety in the phase
I study with solid tumors or hematopoietic malignancies
[32]. Localized skin erythema at the injected site was the
only adverse effect in patients with normal hematopoiesis
[24,33]. Ohta el al. [34] reported that WT1 peptide vaccin-
ation was effective in a pediatric patient with metastatic
alveolar rhabdomyosarcoma who showed poor response
to chemotherapy, and the patient had no adverse effects
other than skin erythema.
For STS, surgery alone or in combination with radio-
therapy and chemotherapy is the mainstream treatment,
and the survival rate has changed just little in recent de-
cades [35]. However, chemotherapy and radiotherapy usu-
ally have significant systemic side effects and it is well
documented that radiation itself is a risk factor of cancer.
WT1 peptide immunotherapy has no significant side ef-
fects other than localized skin erythema and is more
promising in aspect that soft tissue sarcomas are more
common in childhood.
Recently, 75 representative cancer antigens were prior-
itized according to the following criteria: i) therapeutic
function, ii) immunogenicity, iii) role of the antigen in
oncogenicity, iv) specificity, v) expression level and per-
centage of antigen positive cells, vi) stem cell expression,
vii) number of patients with antigen positive cancers,
viii) number of antigenic epitopes, and ix) cellular loca-
tion of antigen expression [26]. They reported that WT1
was at the top of the ranking. WT1 peptide-based im-
munotherapy will be a routine option for malignant
tumor treatment in the near future. Our study suggests
that STS patients are appropriate candidates for WT1
immunotherapy.
This study demonstrates that various types of STS
shows positive cytoplasmic immunostaining for WT1
and STS patients should be considered candidates for
WT1 peptide-based immunotherapy, particularly in cases
of rhabdomyosarcoma and MPNST. To validate the role
of WT1 as a prognostic factor, further studies for molecu-
lar pathways and survival analyses in larger cohorts would
be helpful.
Conclusions
Our study revealed that WT-1 was expressed in the
cytoplasm of the tumor cells of a large number of STS
using immunohistochemistry. Rhabdomyosarcomas and
MPNST showed WT1 expression in a high proportion.
WT1 expression was related to higher FNCLCC histo-
logic grade and AJCC tumor stage. In the group with
high grade STS, strong WT1 expression was correlatedwith better survival. The immunohistochemical results
were correlated with those of the Western blot. Our data
indicated that the cytoplasmic WT1 expression may
have prognostic significance in high grade STS and vari-
ous kinds of soft tissue sarcomas are candidates for
WT1 targeted immunotherapy.
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